Ritanserin

Ritanserin

Clinical data
ATC code	none
Identifiers
IUPAC name 6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[2,3-b]pyrimidin-5-one
CAS Number	87051-43-2 Y
PubChem (CID)	5074
IUPHAR/BPS	97
ChemSpider	4896 N
UNII	145TFV465S Y
ChEBI	CHEBI:64195 N
ChEMBL	CHEMBL267777 N
ECHA InfoCard	100.163.772
Chemical and physical data
Molar mass	477.569 g/mol
3D model (Jmol)	Interactive image
SMILES CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3
InChI InChI=1S/C27H25F2N3OS/c1-18-24(26(33)32-16-17-34-27(32)30-18)12-15-31-13-10-21(11-14-31)25(19-2-6-22(28)7-3-19)20-4-8-23(29)9-5-20/h2-9,16-17H,10-15H2,1H3 N Key:JUQLTPCYUFPYKE-UHFFFAOYSA-N N
NY (what is this?)

Ritanserin (INN, USAN, BAN) is a serotonin receptor antagonist which was never marketed for clinical use but has been used in scientific research.

Ritanserin was tested in clinical trials for schizophrenia and migraine.

Ritanserin acts as a selective 5-HT_2A (K_i = 0.45 nM) and 5-HT_2C receptor (K_i = 0.71 nM) antagonist. It has relatively low affinity for the H₁, D₂, α₁-adrenergic, and α₂-adrenergic receptors (39-, 77-, 107-, and 166-fold lower relative to 5-HT_2A, respectively). The affinity of ritanserin for the 5-HT_1A receptor is than 1 µM. In addition to its affinity for the 5-HT_2A and 5-HT_2C receptors, ritanserin also binds to and antagonizes the 5-HT_1D, 5-HT_2B, 5-HT_5A, 5-HT₆, and 5-HT₇ receptors.

The atypical antipsychotic risperidone was developed from ritanserin.